InSightec Stock
InSightec develops and manufactures MR-guided Focused Ultrasound technology devices for image-guided acoustic surgery.
Sign up today and learn more about InSightec Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About InSightec Stock
InSightec is the pioneer and global leader in MR guided focused ultrasound technology for image guided acoustic surgery. ExAblate® 2000 system was the first system to use the MR guided focused ultrasound technology. The ExAblate system received CE mark in 2002 and the Food and Drug Administration (FDA) approval in 2004 for the treatment of symptomatic uterine fibroids. ExAblate received the European CE Mark for pain palliation of bone metastases in June 2007 and for adenomyosis in June 2010. This device has won numerous innovation awards and has been used to treat thousands of patients around the world.
Investors
Funding History
| November 2007 | $30.0M |
|---|---|
| December 2012 | $30.9M |
| December 2014 | $59.0M |
| January 2016 | $22.0M |
| December 2017 | $150M |
| March 2020 | $150M |
Management
CFO
Roni Karie
CEO & Chairman
Maurice Ferre, M.D.
CEO and Founder
Kobi Vortman
Press
patents - Apr, 14 2024
Systems and Methods for Selective, Targeted Tissue Disruptionpatents - Apr, 14 2024
Enforced tissue residency of payload molecules by acoustic disruptionpatents - Apr, 14 2024
Systems and methods for registering images obtained using different imaging …patents - Apr, 14 2024
Composite structural adhesive compositions and related methodspatents - Apr, 14 2024
Monitoring tissue permeability during ultrasound proceduresEquityZen Recognized As:
